Kindred Biosciences, Inc. (KIN)
KINPrice: $9.25
Fair Value: 🔒
🔒score
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 ... more
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the li... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Richard Chin |
| IPO Date | 2013-12-12 | CAGR | — |
| Employees | 63 | Website | www.kindredbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KIN chart loading...
Fundamentals
Technicals
| Enterprise Value | $391.70M | P/E Ratio | -9.09 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 5.39 |
| P/CF Ratio | -36.87 | P/FCF Ratio | — |
| EPS | $-1.02 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -81.43% | Gross Margin | 0.89% |
| Operating Margin | -0.47% | Profit Margin | -0.56% |
| ROE | -0.32% | ROA | -0.25% |
| ROCE | -0.22% | Current Ratio | 9.08 |
| Quick Ratio | 9.05 | Cash Ratio | 1.69 |
| Debt/Equity | 0.3 | Interest Coverage | -10.92 |
| Altman Z Score | — | Piotroski Score | — |